Cumberland Pharmaceuticals Inc. – NASDAQ:CPIX
Cumberland Pharmaceuticals stock price today
Cumberland Pharmaceuticals stock price monthly change
Cumberland Pharmaceuticals stock price quarterly change
Cumberland Pharmaceuticals stock price yearly change
Cumberland Pharmaceuticals key metrics
Market Cap | 30.89M |
Enterprise value | 28.99M |
P/E | -4.95 |
EV/Sales | 0.69 |
EV/EBITDA | 70.25 |
Price/Sales | 0.66 |
Price/Book | 0.76 |
PEG ratio | 0.08 |
EPS | -0.59 |
Revenue | 38.82M |
EBITDA | 222.02K |
Income | -8.41M |
Revenue Q/Q | -7.88% |
Revenue Y/Y | -3.08% |
Profit margin | -13.26% |
Oper. margin | -13.58% |
Gross margin | 78.29% |
EBIT margin | -13.58% |
EBITDA margin | 0.57% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCumberland Pharmaceuticals stock price history
Cumberland Pharmaceuticals stock forecast
Cumberland Pharmaceuticals financial statements
| Jun 2023 | 10.88M | 872.2K | 8.01% |
|---|---|---|---|
| Sep 2023 | 10.08M | -1.04M | -10.4% |
| Dec 2023 | 9.35M | -6.29M | -67.26% |
| Mar 2024 | 8.49M | -1.94M | -22.9% |
| Jun 2023 | 89375360 | 52.53M | 58.78% |
|---|---|---|---|
| Sep 2023 | 87750944 | 52.09M | 59.37% |
| Dec 2023 | 81776075 | 52.51M | 64.22% |
| Mar 2024 | 81509518 | 54.31M | 66.64% |
| Jun 2023 | 5.23M | -96.80K | -3.27M |
|---|---|---|---|
| Sep 2023 | 1.23M | -95.07K | -882.59K |
| Dec 2023 | 1.04M | 260.63K | -1.48M |
| Mar 2024 | -2.13M | -58.18K | 2.42M |
Cumberland Pharmaceuticals alternative data
| Aug 2023 | 85 |
|---|---|
| Sep 2023 | 85 |
| Oct 2023 | 85 |
| Nov 2023 | 85 |
| Dec 2023 | 85 |
| Jan 2024 | 85 |
| Feb 2024 | 85 |
| Mar 2024 | 91 |
| Apr 2024 | 91 |
| May 2024 | 91 |
| Jun 2024 | 91 |
| Jul 2024 | 91 |
Cumberland Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Oct 2024 | 620 | 0 |
| Nov 2024 | 11688 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | YOUNG CAROLINE director | Common Stock | 16 | $1.32 | $21 | ||
Purchase | JONES JAMES director | Common Stock | 75 | $1.32 | $99 | ||
Purchase | KAZIMI A J director, 10 perc.. | Common Stock | 75 | $1.32 | $99 | ||
Purchase | KROGULSKI KENNETH director | Common Stock | 474 | $1.32 | $626 | ||
Purchase | YOUNG CAROLINE director | Common Stock | 16 | $1.15 | $18 | ||
Purchase | JONES JAMES director | Common Stock | 75 | $1.15 | $86 | ||
Purchase | KAZIMI A J director, 10 perc.. | Common Stock | 75 | $1.15 | $86 | ||
Purchase | KROGULSKI KENNETH director | Common Stock | 474 | $1.15 | $545 | ||
Purchase | YOUNG CAROLINE director | Common Stock | 16 | $1.09 | $17 | ||
Purchase | JONES JAMES director | Common Stock | 75 | $1.11 | $83 |
| Patent |
|---|
Application Filling date: 26 Jan 2022 Issue date: 28 Jul 2022 |
Application Filling date: 28 Mar 2022 Issue date: 14 Jul 2022 |
Application Filling date: 28 Mar 2022 Issue date: 7 Jul 2022 |
Application Filling date: 14 Jan 2022 Issue date: 5 May 2022 |
Application Filling date: 17 Jan 2021 Issue date: 13 May 2021 |
Application Filling date: 23 Oct 2020 Issue date: 15 Apr 2021 |
Grant Filling date: 27 Jan 2020 Issue date: 23 Feb 2021 |
Application Filling date: 25 Sep 2020 Issue date: 21 Jan 2021 |
Application Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists Filling date: 16 Jun 2020 Issue date: 3 Dec 2020 |
Application Filling date: 29 Jun 2020 Issue date: 8 Oct 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 5 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 12 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Cumberland Pharmaceuticals stock today?
One share of Cumberland Pharmaceuticals stock can currently be purchased for approximately $3.14.
-
When is Cumberland Pharmaceuticals's next earnings date?
Unfortunately, Cumberland Pharmaceuticals's (CPIX) next earnings date is currently unknown.
-
Does Cumberland Pharmaceuticals pay dividends?
No, Cumberland Pharmaceuticals does not pay dividends.
-
How much money does Cumberland Pharmaceuticals make?
Cumberland Pharmaceuticals has a market capitalization of 30.89M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.85% to 39.55M US dollars.
-
What is Cumberland Pharmaceuticals's stock symbol?
Cumberland Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "CPIX".
-
What is Cumberland Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Cumberland Pharmaceuticals?
Shares of Cumberland Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cumberland Pharmaceuticals's key executives?
Cumberland Pharmaceuticals's management team includes the following people:
- Mr. A. J. Kazimi Founder, Chairman, Pres & Chief Executive Officer(age: 67, pay: $787,000)
- Mr. Leo B. Pavliv Executive Vice President of Operations & Chief Devel. Officer(age: 64, pay: $490,240)
- Mr. Martin E. Cearnal Executive Vice President, Chief Commercial Officer & Director(age: 80, pay: $381,740)
- Mr. James Lowrance Herman Senior Vice President of National Accounts & Chief Compliance Officer(age: 70, pay: $310,650)
-
Is Cumberland Pharmaceuticals founder-led company?
Yes, Cumberland Pharmaceuticals is a company led by its founder Mr. A. J. Kazimi.
-
How many employees does Cumberland Pharmaceuticals have?
As Jul 2024, Cumberland Pharmaceuticals employs 91 workers.
-
When Cumberland Pharmaceuticals went public?
Cumberland Pharmaceuticals Inc. is publicly traded company for more then 16 years since IPO on 11 Aug 2009.
-
What is Cumberland Pharmaceuticals's official website?
The official website for Cumberland Pharmaceuticals is cumberlandpharma.com.
-
Where are Cumberland Pharmaceuticals's headquarters?
Cumberland Pharmaceuticals is headquartered at 2525 West End Avenue, Nashville, TN.
-
How can i contact Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals's mailing address is 2525 West End Avenue, Nashville, TN and company can be reached via phone at +61 52550068.
Cumberland Pharmaceuticals company profile:
Cumberland Pharmaceuticals Inc.
cumberlandpharma.comNASDAQ
91
Drug Manufacturers - Specialty & Generic
Healthcare
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Nashville, TN 37203
CIK: 0001087294
ISIN: US2307701092
CUSIP: 230770109
